- Home
- CERT
CERT
Certara Inc.
as 01-17-2025 4:00pm EST
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | RADNOR |
| Market Cap: | 1.8B | IPO Year: | 2020 |
| Target Price: | $15.92 | AVG Volume (30 days): | 1.0M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.41 - $19.87 | Next Earning Date: | 02-27-2025 |
| Revenue: | $372,797,000 | Revenue Growth: | 5.62% |
| Revenue Growth (this year): | 10.2% | Revenue Growth (next year): | 10.01% |
Latest Certara Inc. News
CERT Breaking Stock News: Dive into CERT Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
Argus Research
4 days ago
CERT: What does Argus have to say about CERT?
Simply Wall St.
10 days ago
Certara (NASDAQ:CERT) Will Be Hoping To Turn Its Returns On Capital Around
GlobeNewswire
16 days ago
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Argus Research
a month ago
CERT: What does Argus have to say about CERT?
Argus Research
a month ago
CERT: Lowering target price to $9.00
Argus Research
a month ago
CERT: Raising target price to $10.00
Insider Monkey
a month ago
Cautious Spending By Large Biopharma Client Dragged Certara (CERT) in Q3
Compare CERT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CERT Certara Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.